tuspetinib   Click here for help

GtoPdb Ligand ID: 12010

Synonyms: example 8 [US10870639B2] | HM-43239 | HM43239
Compound class: Synthetic organic
Comment: HM43239 is an orally active, clinical stage compound that inhibits a number of kinases that are active in myeloid malignancies, including FLT3, SYK, mutant forms of cKIT, JAK1/2, and other kinases [1]. It is intended as a treament for patients with relapsed/refractory acute myeloid leukemia (AML). We matched its chemical structure to the INN 'tuspetinib' that was released in the WHO's proposed INN list 127 (21 July 2022).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 68.87
Molecular weight 500.25
XLogP 5.97
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C[C@@H]1N[C@H](C)CN(C1)Cc1cc(Nc2ncc(c(n2)c2c[nH]c3c2ccc(c3)C)Cl)cc(c1)C1CC1
Isomeric SMILES C[C@@H]1CN(C[C@@H](N1)C)Cc1cc(cc(c1)Nc1ncc(c(n1)c1c[nH]c2c1ccc(c2)C)Cl)C1CC1
InChI InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
InChI Key FZLSDZZNPXXBBB-KDURUIRLSA-N
No information available.
Summary of Clinical Use Click here for help
Having received orphan drug designation from the FDA for treatment of acute myeloid leukemia (AML) in 2018, HM43239 was granted FDA fast track designation for this indication in May 2022. HM43239 has demonstrated clinical efficacy in a broad diversity of relapsed/refractory AML patients, including those whose disease failed to respond to other FLT3 inhibitors.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2 Interventional Aptose Biosciences Inc.